Forty Seven Inc. (NASDAQ: FTSV) shares skyrocketed on Monday after the company announced that it would be acquired by Gilead Sciences Inc. (NASDAQ: GILD). Both the Gilead and Forty Seven boards of directors unanimously approved the transaction, and it is anticipated to close during the second quarter of 2020.
Under the terms of the deal, Gilead will acquire Forty Seven for $95.50 per share in cash, for a total value of $4.9 billion.
Compared to the 50-day and 200-day moving averages of $41.97 and $18.06, Gilead is paying premiums of 127.5% and 428.8%, respectively.
It’s worth noting that Forty Seven only came public over the summer of 2018, and shares traded as low as $5 this past fall.
Through the addition of Forty Seven’s investigational lead product candidate, magrolimab, the acquisition will strengthen Gilead’s immuno-oncology research and development portfolio. Magrolimab is a monoclonal antibody in clinical development for the treatment of several cancers for which new, transformative medicines are urgently needed, including myelodysplastic syndrome, acute myeloid leukemia and diffuse large B-cell lymphoma.
Daniel O’Day, board chair and CEO of Gilead, commented:
This agreement builds on Gilead’s presence in immuno-oncology and adds significant potential to our clinical pipeline. Magrolimab complements our existing work in hematology, adding a non-cell therapy program that complements Kite’s pipeline of cell therapies for hematological cancers. With a profile that lends itself to combination therapies, magrolimab could potentially have transformative benefits for a range of tumor types. We are looking forward to working with the highly experienced team at Forty Seven to help patients with some of the most challenging forms of cancer.
Shares of Forty Seven closed Friday at $58.00 but up almost 62% at $93.75 early Monday. Gilead Sciences stock traded up 2% to $70.74 on last look, in a 52-week range of $60.89 to $78.88.
Cash Back Credit Cards Have Never Been This Good
Credit card companies are at war, handing out free rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. See our top picks for the best credit cards today. You won’t want to miss some of these offers.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
